title: Incidence of chronic kidney disease in patients with atrial fibrillation and its relevance for prescribing new oral antithrombotic drugs.
authors.forename: J
authors.initials: J
authors.lastname: Kooiman
authors.forename: W R
authors.initials: WR
authors.lastname: van de Peppel
authors.forename: F J M
authors.initials: FJ
authors.lastname: van der Meer
authors.forename: M V
authors.initials: MV
authors.lastname: Huisman
mesh_terms: D000284:Administration, Oral; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000453:epidemiology; D001562:Benzimidazoles / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D015415:Biomarkers / Q000097:blood; D002908:Chronic Disease; D003404:Creatinine / Q000097:blood; D000069604:Dabigatran; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D005919:Glomerular Filtration Rate; D006801:Humans; D015994:Incidence; D007668:Kidney / Q000378:metabolism / Q000503:physiopathology; D007674:Kidney Diseases / Q000175:diagnosis / Q000453:epidemiology* / Q000378:metabolism / Q000503:physiopathology; D009025:Morpholines / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D009426:Netherlands / Q000453:epidemiology; D018579:Patient Selection; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D000069552:Rivaroxaban; D012720:Severity of Illness Index; D013876:Thiophenes / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D015091:beta-Alanine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics
chemical_list: D001562:Benzimidazoles; D015415:Biomarkers; D005343:Fibrinolytic Agents; D009025:Morpholines; D013876:Thiophenes; D015091:beta-Alanine; D000069552:Rivaroxaban; D003404:Creatinine; D000069604:Dabigatran